The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular Disease
Abstract
Limited data suggest that HMG-CoA reductase inhibitors (statins) may slow loss of renal function in individuals with chronic renal insufficiency. This study was conducted to determine whether pravastatin reduced rates of loss of renal function in people with moderate chronic renal insufficiency. This was a post hoc subgroup analysis of a randomized double-blind placebo controlled trial. Data were analyzed from the CARE study (a randomized trial of pravastatin versus placebo in 4159 participants with previous myocardial infarction and total plasma cholesterol < 240 mg/dl). Participants with estimated GFR (MDRD-GFR) < 60 ml/min per 1.73 m(2) body surface area at baseline were considered to have moderate chronic renal insufficiency. Multivariate regression was used to calculate rates of decline in MDRD-GFR for individuals receiving pravastatin and placebo, controlling for prospectively determined covariates that might influence rates of renal function loss. Change in renal function could be calculated in 3384 individuals, of whom 690 (20.4%) had MDRD-GFR < 60 ml/min per 1.73 m(2) and were eligible for inclusion. Among all individuals with MDRD-GFR < 60 ml/min per 1.73 m(2)), the MDRD-GFR decline in the pravastatin group was not significantly different from that in the placebo group (0.1 ml/min per 1.73 m(2)/yr slower; 95% CI, -0.2 to 0.4; P = 0.49). However, there was a significant stepwise inverse relation between MDRD-GFR before treatment and slowing of renal function loss with pravastatin use, with more benefit in those with lower MDRD-GFR at baseline (P = 0.04). Rate of change in MDRD-GFR in the pravastatin group was 0.6 ml/min per 1.73 m(2)/yr slower than placebo (95% CI, -0.1 to 1.2; P = 0.07) in those with MDRD-GFR < 50 ml/min, and 2.5 ml/min per 1.73 m(2)/yr slower (95% CI, 1.4 to 3.6 slower; P = 0.0001) in those with MDRD-GFR < 40 ml/min per 1.73 m(2)/yr. Pravastatin also reduced rates of renal loss to a greater extent in participants with than without proteinuria at baseline (P = 0.006). It is concluded that pravastatin may slow renal function loss in individuals with moderate to severe kidney disease, especially those with proteinuria. These findings require confirmation by a large randomized trial conducted specifically in people with chronic renal insufficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Simvastatin, an HMG–Coenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month
O'Driscoll, G., Green, D., & Taylor, R. R. (1997) · Circulation · doi:10.1161/01.cir.95.5.1126 · Cited by 952
Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency
Culleton, B. F., Larson, M. G., Wilson, P. W. F., Evans, J. C., Parfrey, P. S., & Levy, D. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00773.x · Cited by 838
A multi-rule Shewhart chart for quality control in clinical chemistry.
Westgard, J. O., Barry, P. L., Hunt, M. R., & Groth, T. (1981) · Clinical Chemistry · doi:10.1093/clinchem/27.3.493 · Cited by 831
Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency
Shlipak, M. G., Fried, L. F., Crump, C., Bleyer, A. J., Manolio, T. A., Tracy, R. P., Furberg, C. D., & Psaty, B. M. (2003) · Circulation · doi:10.1161/01.cir.0000042700.48769.59 · Cited by 810
Coresh, J., Astor, B. C., McQuillan, G., Kusek, J., Greene, T., Van Lente, F., & Levey, A. S. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32765 · Cited by 717
Effect of lipid reduction on the progression of renal disease: A meta-analysis
Fried, L. F., Orchard, T. J., & Kasiske, B. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00487.x · Cited by 672
Stehouwer, C. D. A., Gall, M.-A., Twisk, J. W. R., Knudsen, E., Emeis, J. J., & Parving, H.-H. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1157 · Cited by 652
Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey
Jones, C., McQuillan, G., Kusek, J., Eberhardt, M., Herman, W., Coresh, J., Salive, M., Jones, C., & Agodoa, L. (1998) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(98)70074-5 · Cited by 572
The Microinflammatory State in Uremia: Causes and Potential Consequences
KAYSEN, G. A. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271549 · Cited by 473
LEVEY, A. S., GREENE, T., BECK, G. J., CAGGIULA, A. W., KUSEK, J. W., HUNSICKER, L. G., & KLAHR, S. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10112426 · Cited by 399
Tonelli, M., Moy, L., Sacks, F. M., Kiberd, B., Curhan, G., & for the Cholesterol and Recurrent Events (CARE) Trial Investigators (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00010 · Cited by 278 · cited 1×
“For example, it seems unlikely that people with previous myocardial infarction could be prospectively studied, because statins improve clinical outcomes in this population and the magnitude of benefit appears similar in people with and without normal kidney function (37).”
BackgroundSelf-citationFerro, D., Parrotto, S., Basili, S., Alessandri, C., & Violi, F. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00771-3 · Cited by 207
Golan, L., Birkmeyer, J. D., & Welch, H. G. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-9-199911020-00005 · Cited by 160
The role of lipids in renal disease: Future challenges
Keane, W. F. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07503.x · Cited by 155
Recent advances in statins and the kidney
Oda, H., & Keane, W. F. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07101.x · Cited by 150
Jager, A., van Hinsbergh, V. W. M., Kostense, P. J., EMEIS, J. J., Nijpels, G., Dekker, J. M., Heine, R. J., Bouter, L. M., & Stehouwer, C. D. A. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000013786.80104.d4 · Cited by 128
Sacks, F. M., Pfeffer, M. A., Moyé, L. A., Brown, L. E., Hamm, P., Cole, T. G., HAWKINS, C. M., Braunwald, E., & The CARE Investigators (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90276-q · Cited by 125
Self-citationGarg, A. X., Blake, P. G., Clark, W. F., Clase, C. M., Haynes, R. B., & MOIST, L. M. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00001.x · Cited by 113
Kurakata, S., Kada, M., Shimada, Y., KOMAI, T., & Nomoto, K. (1996) · Immunopharmacology · doi:10.1016/0162-3109(96)00108-7 · Cited by 99
Sarnak, M. J., Poindexter, A. E., Wang, S.-R., Beck, G. J., Kusek, J. W., Marcovina, S. M., Greene, T., & Levey, A. S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00677.x · Cited by 93
Katznelson, S., & KOBASHIGAWA, J. A. (1995) · PubMed · Cited by 71
Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment
Halstenson, C. E., Triscari, J. M., DeVault, A. R., Shapiro, B. E., Keane, W. F., & Pan, H. (1992) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1992.tb03816.x · Cited by 53
Clark, W. F., Churchill, D. N., Forwell, L., Macdonald, G., & Foster, S. (2000) · Europe PMC (PubMed Central) · Cited by 52
SCHLUCHTER, M. D., Greene, T., & Beck, G. J. (2001) · Statistics in Medicine · doi:10.1002/sim.720 · Cited by 51
Guijarro, C., & Keane, W. F. (1996) · PubMed · Cited by 38
Pravastatin experience in elderly and non-elderly patients
Mellies, M. J., DeVault, A. R., Kassler-Taub, K., McGovern, M. E., & Pan, H. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90105-4 · Cited by 21
Eikelboom, J. W., & Hankey, G. J. (2001) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200105000-00013 · Cited by 21
Effects of Hypercholesterolemia on Renal Hemodynamics: Study in Patients with Nephrotic Syndrome
Fuíano, G., Esposito, C., Sepe, V., G., C., Bovino, M., Rosa, M., Balletta, M., Bellinghieri, G., Conte, G., Cianciaruso, B., et al. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000189106 · Cited by 20
Treatment of hyperlipidemia in chronic progressive renal disease
Kasiske, B. L., Mp, O., Kim, Y., & Keane, W. F. (1993) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199307000-00011 · Cited by 13
Cited by
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar, N. S., McMurray, J. J. V., Velazquez, E. J., Solomon, S. D., Kober, L., Rouleau, J.-L., White, H. D., Nordlander, R., Maggioni, A., Dickstein, K., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041365 · Cited by 1,917
Pleiotropic Effects of Statins on the Cardiovascular System
Oesterle, A., Laufs, U., & Liao, J. K. (2017) · Circulation Research · doi:10.1161/circresaha.116.308537 · Cited by 1,247
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults
Kurella, M., Lo, J. C., & Chertow, G. M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010106 · Cited by 709
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
Vaziri, N. D. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00099.2005 · Cited by 538
Metadata
- Authors
- Tonelli, M., Moyé, L., Sacks, F. M., Cole, T., & Curhan, G. C.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2003-06
- Volume
- 14
- Issue
- 6
- Pages
- 1605-1613
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2146311281
- Cited by
- 306
- References
- 39
- FWCI
- 17.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.